Altrax

Quick links to important sections

Altrax

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Altrax

Property Description
Active Ingredients Caffeine, Ibuprofen, Loratadine, Phenylephrine
Form Oral tablet or solution
Pharmacological Class Multi-component analgesic, NSAID, H1-antihistamine, and decongestant combination
Common Use Simultaneous relief of multiple cold, flu, and allergy-related symptoms
Origin Synthetic

1. Altrax: A Fixed-Dose Combination and Pharmacological Profile

Altrax is a synthetic, multi-component medicinal product supplied for oral use as a fixed-dose combination. Its identity is established by the unique co-formulation of four active pharmaceutical ingredients (APIs) in a single unit. The formulation's broad pharmacological profile is classified as a combination of a nonsteroidal anti-inflammatory drug (NSAID), a second-generation H1-antihistamine, a sympathomimetic decongestant, and a central nervous system (CNS) stimulant. This differentiated structure ensures that the product addresses multiple symptomatic pathways concurrently, setting it apart from single-ingredient analgesics.

2. The Four Active Ingredients of Altrax

The composition of Altrax relies on the four distinct agents: Ibuprofen, Loratadine, Phenylephrine, and Caffeine. Ibuprofen functions as an NSAID, a class of drugs recognized for reducing mediators of pain and fever. The product incorporates Loratadine, a second-generation H1-receptor antagonist, which is recognized for its non-sedating profile when compared to older antihistamine classes. Phenylephrine acts as an alpha-1 adrenergic agonist, a type of decongestant used to reduce swelling in nasal membranes. Finally, Caffeine is included as a methylxanthine and CNS stimulant, a component often included in multi-symptom cold relief products to promote alertness and mitigate fatigue.

3. General Purpose of the Multi-Component Formulation

The design of the Altrax formulation is strategic, aimed at providing coordinated, systemic symptomatic relief for multiple concurrent discomforts. The multi-action approach addresses pain, fever, inflammation, and allergic symptoms, while the inclusion of the stimulant helps manage associated fatigue. This combination principle utilizes the co-administration of these classes of agents to manage the diverse symptom set associated with self-limiting conditions. The overarching purpose is to integrate the effects of an analgesic, an antihistamine, a decongestant, and a stimulant into a comprehensive therapeutic approach.

Regulatory References

  1. Loratadine: MedlinePlus Drug Information

What side effects are possible with Altrax?

Possible Side Effects and Safety Information: Altrax

The safety profile for Altrax, based on regulatory documentation, involves adverse reactions categorized by frequency and the body system affected.

Adverse Reaction Categories

Adverse reactions are formally classified using frequency categories derived from clinical trial data and post-marketing surveillance. These classifications include Very Common, Common, Uncommon, Rare, and Very Rare effects, with reports also included under Frequency Not Known when estimation is not possible from available data. Adverse reactions are grouped by System-Organ-Class (SOC), such as Nervous System Disorders, Gastrointestinal Disorders, and Cardiac Disorders.

Frequency Category Example System-Organ-Classes Involved
Very Common General systemic effects (e.g., drowsiness), Anticholinergic effects (e.g., dry mouth)
Common Central Nervous System (e.g., dizziness, headache), Gastrointestinal (e.g., constipation)
Rare Serious or clinically significant reactions (see below)

Serious Adverse Reactions and Safety Warnings

Serious Adverse Reactions highlighted in official safety information include QT interval prolongation and Torsades de Pointes, which are alterations in the heart’s electrical activity that can lead to abnormal, potentially life-threatening heart rhythms and cardiac arrest. Other serious reactions reported include Acute Generalized Exanthematous Pustulosis (AGEP) and other severe skin reactions, and seizures.

Safety-Related Restrictions and Contraindications: Altrax is formally contraindicated in patients with a known history of QT interval prolongation, existing uncorrected heart rhythm disturbances, or in early pregnancy. Caution is mandated for patients with risk factors for QT prolongation (e.g., specific cardiovascular diseases, low potassium or magnesium levels). Use is generally not recommended in elderly patients due to reduced drug clearance and increased vulnerability to certain adverse effects, such as confusion and over-sedation.

Population-Specific and Dose-Related Safety

Population-Specific Considerations focus on the elderly, where a reduced starting dose and close monitoring are necessary due to potentially increased sensitivity to effects like somnolence. Official documents also note that Altrax may cross the placental barrier and advise against use during the early part of pregnancy. Dose-related patterns include drowsiness being commonly transitory and potentially dose-related, often resolving with continued therapy or dose reduction.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Altrax is considered a severe event requiring immediate medical intervention, as documented in regulatory information for its multi-component profile.

Documented Manifestations and Severe Outcomes

Overdose presentations are officially documented to affect multiple systems. Initial signs may include severe nausea, vomiting, and epigastric pain. Central Nervous System (CNS) manifestations range from lethargy and drowsiness to signs of stimulation, such as tremor and agitation. Cardiovascular findings frequently include tachycardia, palpitations, and hypertension.

The combination carries specific risks of severe, life-threatening outcomes, including seizures and coma. Critical organ risks involve the potential for acute renal failure and significant gastrointestinal bleeding, alongside severe cardiac arrhythmia and hypertensive crisis.

Required Emergency Actions

Official government guidance mandates that anyone who suspects an overdose must seek immediate medical attention and contact emergency services without delay. No specific antidote is known for the combination product; therefore, management is strictly symptomatic and supportive treatment. Hospital monitoring, including ECG and CNS observation, is typically required for several hours. Regulatory labeling notes an increased risk of severe CNS effects, particularly excitation and seizures, in pediatric and elderly populations following an overdose.

Therapeutic Uses of Altrax

What Altrax Treats: Main Uses and Benefits

The combination of four active therapeutic components is considered relevant in situations involving acute, multi-symptom discomfort arising from common cold, influenza, or seasonal allergies. The formulation is applied in contexts where several symptoms cluster into patterns, such as headache, fever, nasal congestion, and allergic responses, requiring supportive management. This integrated approach may assist with maintaining a sense of stability when symptoms are more noticeable during difficult, episodic manifestations.

The medication is applied in addressing groups of systemic symptoms, including headaches, generalized body aches and pains, and fever, that may appear suddenly or intensify over time. It is also relevant for easing symptoms related to heightened physiological activity, such as runny nose and sneezing, which may create noticeable functional strain. The product is used across therapeutic domains where short-term symptomatic assistance is appropriate for easing discomfort and helping to address symptoms that interfere with daily functioning.

“This formulation supports patients during difficult episodes by easing distress and contributing to easing the overall symptom load.”

Symptomatic Focus: Multi-Systemic Discomfort

Eligibility and Restrictions for Use

The eligibility for using Altrax is strictly defined by official regulatory criteria, reflecting the restrictions associated with its four active components. Use is officially established for adults and adolescents aged 12 years and older who meet all official eligibility criteria. The medicine is not recommended for children younger than 12 years of age. Use in elderly patients is permitted but requires caution due to a documented increased risk of adverse events.


Populations Who Must Not Use Altrax (Contraindicated)

According to official regulatory labeling, this medicine is contraindicated and must not be used by individuals with:

  • Known hypersensitivity to Ibuprofen, any nonsteroidal anti-inflammatory drug (NSAID), or Aspirin.
  • Active gastrointestinal bleeding or peptic ulceration.
  • Severe heart failure, severe renal failure, or severe hepatic failure.
  • Current or recent use (within 14 days) of Monoamine Oxidase Inhibitors (MAOIs).

Pregnancy and Restricted Use

The medicine is contraindicated during the third trimester of pregnancy. It is not recommended during the first and second trimesters, or while breastfeeding.

Use also requires caution in patients with mild-to-moderate organ impairment, high blood pressure, diabetes, glaucoma, or a history of bleeding disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Altrax is defined by the combined pharmacology of its four active components, resulting in documented restrictions and contraindications as stated in regulatory labels.

Regulatory Restrictions and Contraindications

Co-administration is contraindicated with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of severe hypertensive reactions associated with the Phenylephrine component. A 14-day washout period is required after stopping an MAOI before initiation. Use is also restricted immediately before or after Coronary Artery Bypass Graft (CABG) Surgery due to the Ibuprofen component.

Pharmacokinetic and Pharmacodynamic Interference

Officially documented interactions include exposure modification. The Ibuprofen component causes an elevation of plasma Lithium levels and reduces its renal clearance, and may enhance Methotrexate toxicity. Additionally, CYP3A4 inhibitors may increase the plasma concentration of the Loratadine component.

Pharmacodynamic effects include the increased risk of gastrointestinal bleeding when combined with Anticoagulants (such as Warfarin) or Alcohol. The Ibuprofen component may also reduce the efficacy of diuretics. To avoid interference with the antiplatelet effect of low-dose Aspirin, Aspirin must be administered at least 2 hours prior to Altrax. Caution is noted for elderly patients, who have a greater risk for serious gastrointestinal adverse events when taking the NSAID component.

Mechanism of Action

The Mechanism of Action of Altrax: Pharmacodynamics

Altrax exerts its primary effect as an inverse agonist at the Histamine H1 receptor across both peripheral tissues and the central nervous system (CNS). This molecular interaction stabilizes the H1 receptor in an inactive conformation, thereby modulating the histaminergic signaling pathway by preventing its activation by endogenous histamine. In peripheral systems, this action limits histamine-mediated vascular and sensory nerve responses.

Within the CNS, Altrax readily crosses the blood-brain barrier. The blockade of CNS H1 receptors modifies signaling within subcortical pathways that regulate arousal, leading to reduced overall neural activity.

Additionally, the drug engages in non-selective modulation by acting as an antagonist with lower affinity at several other neuroreceptors, including Serotonin 5-HT2A and Muscarinic acetylcholine receptors. This secondary modulation affects dynamics within the serotonergic and cholinergic systems, contributing to peripheral anticholinergic physiological adjustments and the suppression of signaling within the Chemoreceptor Trigger Zone (CTZ).

Dosage and Administration Information

How to Use Altrax: Official Administration Guidelines

The administration of Altrax is governed by a set of instructions that define the route, dosage, frequency, and duration of use. These guidelines ensure the product is used consistently with the parameters established for the product.


Administration Scope

Instruction Domain Labeled Guideline
Route of Administration Oral route only (Tablet and Solution forms).
Standard Dosing The standard adult unit dose is two (2) oral units per administration.
Maximum Limit The maximum prescribed dosage is eight (8) oral units within any 24-hour period.
Dosing Frequency Administration may occur every four (4) to six (6) hours as needed, ensuring a minimum interval of four (4) hours between doses.
Duration Constraint Treatment is restricted to short-term use and must not exceed seven (7) consecutive days.

Contextual and Population-Specific Rules

The product may be administered without regard to food or water intake. If Altrax is formulated as an extended-release tablet, the unit must be swallowed whole and must not be crushed or chewed. Usage is officially not recommended for pediatric patients under 12 years of age.


Official Use Protocol: The instructions dictate a procedural structure beginning with the administration of the two-unit standard dose, maintaining the minimum four-hour interval, and strictly adhering to the maximum daily limit and the overall seven-day course constraint. This framework defines the exact boundaries for its non-advisory, label-based administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Altrax

The research base for Altrax is rooted in the established data for its four individual active components and in studies that explore the observed patterns when combining certain analgesic, antihistamine, and decongestant ingredients. The official scientific literature primarily consists of short-term, randomized controlled trials (RCTs), systematic reviews, and meta-analyses.


Evidence for Managing Acute, Moderate Pain

This section summarizes the research conducted on the analgesic component, which consists of Ibuprofen and Caffeine. The combination was evaluated in research examining measurements of pain symptoms, such as headache and other acute body aches.

Studies on the Analgesic-Stimulant Combination

Research explored the use of the Ibuprofen and Caffeine combination in short-term, single-dose RCTs. These studies typically involved otherwise healthy adults experiencing episodes of moderate-to-severe pain, where outcomes related to physical discomfort were precisely measured. Research highlights changes measured during the study period, with the combination of Ibuprofen and Caffeine producing measurements of pain relief and pain intensity that differed from those reported for Ibuprofen or Caffeine used alone. The follow-up durations were limited, consistent with the study design intended to assess the single-dose effect.


Evidence for Multi-Systemic Cold, Flu, and Allergy Discomfort

This area of research applies to studies of the combination principle of Altrax, which was evaluated for its use in conditions involving periods of heightened symptom activity, such as the common cold, flu, or seasonal allergies.

Symptom-Specific Outcomes Evaluated in Clinical Trials

Researchers utilized RCTs and systematic reviews of multi-component combinations (including an NSAID, an antihistamine, and a decongestant) to evaluate outcomes related to systemic imbalance. Studies monitored overall symptom severity scores, which are designed to capture multiple outcomes related to systemic or functional imbalance concurrently. Findings describe patterns observed in the studies where combination products were compared to placebo groups regarding overall symptom scores.


Key Areas of Research Uncertainty and Gaps

Evidence highlights what is known—and what is still uncertain—about this combination product. The core limitations in the evidence landscape include the consistency of certain ingredient effects: findings were mixed, and there is ongoing regulatory discussion regarding the efficacy of the oral decongestant component, Phenylephrine, at the typical non-prescription dosage. Recent research describes patterns where measured outcomes for oral Phenylephrine were not significantly different from those observed in studies of a placebo. Furthermore, data for certain groups, such as children and older adults, remain insufficient in the primary research base.

Frequently Asked Questions (FAQ)

Common questions about Altrax (FAQ)

Q: Does Altrax treat the cause or just the symptoms?

A: Altrax is officially designed to provide coordinated, systemic symptomatic relief for several concurrent discomforts. The multi-component formulation, which combines an analgesic, an antihistamine, a decongestant, and a stimulant, works to manage the overall collection of symptoms associated with self-limiting conditions. According to official product information, its purpose is to address symptoms rather than the underlying cause of the condition.

Q: Is it common to feel tired when taking Altrax?

A: Official safety documents list drowsiness as a Very Common side effect and dizziness as Common. While the product contains a central nervous system (CNS) stimulant (Caffeine), which is often included to help mitigate fatigue, some individuals may still experience these CNS effects. Regulatory documents note that drowsiness is commonly transitory and potentially dose-related.

Q: Is it safe to drink alcohol while taking Altrax?

A: Official regulatory documents define the co-administration of Altrax with alcohol as being associated with an increased risk of gastrointestinal bleeding. This risk is related to the Ibuprofen component of the drug, and this restriction is documented in the product's official safety information.

Q: Can Altrax affect my ability to drive?

A: Due to the potential for central nervous system side effects, such as drowsiness (Very Common) and dizziness (Common), official regulatory guidance notes that caution is necessary when performing skilled tasks like driving or operating machinery. This is based on the known pharmacological effects of the components.

Q: Is it possible to be allergic to Altrax?

A: Official regulatory documents state that Altrax is formally contraindicated if a patient has a known history of hypersensitivity (allergic reaction) to Ibuprofen, any nonsteroidal anti-inflammatory drug (NSAID), or Aspirin. As with any medication, hypersensitivity to any of the active or inactive components is a possibility described in the product information.

Q: Do people usually take Altrax in the morning or at night?

A: Altrax is an 'as needed' medicine that can be administered every four to six hours, without regard to food intake. The formulation contains a second-generation antihistamine and a CNS stimulant (Caffeine), which may influence administration timing based on the user's general symptomatic profile and daily activities.

Q: What happens when you stop taking Altrax?

A: The administration of Altrax is restricted to short-term use, not exceeding seven consecutive days. Due to this defined course of use, regulatory documents and official product information do not define patterns of physical dependence or withdrawal associated with this short-term usage constraint.

Q: Is Altrax the same type of drug as [Similar Drug Name]?

A: Altrax is officially classified as a multi-component analgesic, NSAID, H1-antihistamine, and decongestant combination. Its identity is established by the co-formulation of four distinct pharmacological classes: Ibuprofen, Loratadine, Phenylephrine, and Caffeine. This combination approach sets it apart from single-ingredient medicines.

Q: Are there any food or drinks I should avoid while on Altrax?

A: The product may be administered without regard to food or water intake. The key restriction noted in official documents is the avoidance of concurrent use of alcohol due to the associated increase in risk for gastrointestinal bleeding.

Q: What happens if I miss a dose of Altrax?

A: Regulatory documents typically define procedures for managing missed doses for as-needed medications. These procedures often focus on maintaining the proper minimum interval between doses and avoiding the administration of a double dose. This specific guidance is detailed in the official prescribing information.

Q: Can Altrax be taken with common pain relievers like ibuprofen?

A: Altrax already contains Ibuprofen as one of its four active ingredients. Regulatory warnings indicate that taking additional Ibuprofen or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) concurrently may increase the risk of adverse effects due to the risk of exceeding the established maximum daily dose.

Q: What should I do if a side effect seems serious?

A: Serious adverse reactions highlighted in official safety information include severe cardiac and dermatological events, such as QT interval prolongation and severe skin reactions. Official materials describe that if symptoms of a serious adverse reaction occur, immediate assessment by a healthcare professional is necessary.

Q: Does Altrax interact with supplements like St. John's Wort?

A: While official labels may not list all herbal supplements, the drug’s components interact with liver enzymes (such as CYP3A4) that can be affected by certain supplements like St. John’s Wort. The full product labeling contains comprehensive drug interaction lists that should be referenced for potential risks associated with supplements.

Q: Is Altrax a controlled substance?

A: Altrax is classified as a multi-component product that combines an NSAID, an antihistamine, a decongestant, and a stimulant. None of the four listed active ingredients (Ibuprofen, Loratadine, Phenylephrine, Caffeine) are typically classified as controlled substances in the United States or most international regulatory schedules.

Q: Is Altrax known to cause mental or mood changes?

A: Official safety information notes that Altrax can cause changes such as confusion and, rarely, seizures (a serious reaction). Caution is mandated for elderly patients due to their documented increased risk for adverse events like confusion and over-sedation.

Q: What are the ingredients in Altrax besides the active one?

A: Official regulatory labels include a complete list of inactive ingredients (excipients). These are the non-active components, such as fillers, coloring agents, or binders, that are used in the manufacturing of the oral tablet or solution formulation. This full list is available within the product’s detailed prescribing information.

Q: Is it normal to feel a mild headache after starting Altrax?

A: According to official safety documents, headache is listed as a Common side effect based on regulatory data from clinical trials and post-marketing reports. It is a known event described in the official product information and safety documentation.

Q: Can I take Altrax if I have a history of heart problems?

A: Altrax is formally contraindicated and must not be used by patients with a history of severe heart failure, existing uncorrected heart rhythm disturbances, or a known history of QT interval prolongation. Caution is mandated for all patients with risk factors for QT prolongation or other cardiovascular issues.

How should Altrax be stored and disposed of?

How to Store and Dispose of Altrax

Altrax oral tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Storage must avoid excessive heat above 40 C and high humidity, meaning the product should not be stored in a bathroom. The tablets must remain in their original container, which should be kept tightly closed and protected from light.

Handling and Disposal

All medicines, including Altrax, must be kept out of the sight and reach of children and pets to prevent accidental ingestion. For disposal, do not flush unused or expired tablets down a toilet or drain. The preferred method is to use an authorized drug take-back program. If this is not an option, the medicine should be mixed with an unappealing substance, placed in a sealed bag or container, and disposed of in the household trash, according to regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Altrax found in:

A-Z Index: